Pivarubicin was developed as a hydrolytically stable alternative to AD 198.  The tertiary trimethyl arrangement (pivalate) sterically hinders esterase-mediated cleavage of the 14-O-acyl linkage with any apparent effect on the PKC-mediated of pivarubicin.  In comparable studies, pivarubicin possesses the functional characteristics of AD 198, including potency against an array of human tumor cell types and circumvention of multiple mechanisms of drug resistance.


​​Innovative therapies
                         Superior outcomes